Ubs Group Ag Xenetic Biosciences, Inc. Transaction History

Ubs Group Ag

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$0.59 - $5.57 $4,093 - $38,644	6,938 Added 754.95%	7,857 $4,000
Q2 2022 Aug 10, 2022	BUY	$0.6 - $1.14 $551 - $1,047	919 New	919 $1,000
Q1 2022 May 16, 2022	SELL	$0.88 - $1.37 $5,331 - $8,299	-6,058 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.08 $4,333 - $7,096	3,412 Added 128.95%	6,058 $8,000
Q3 2021 Nov 15, 2021	SELL	$1.73 - $5.3 $4,435 - $13,589	-2,564 Reduced 49.21%	2,646 $5,000
Q2 2021 Aug 13, 2021	BUY	$1.57 - $2.45 $6,656 - $10,388	4,240 Added 437.11%	5,210 $11,000
Q1 2021 May 12, 2021	BUY	$2.01 - $3.5 $1,949 - $3,395	970 New	970 $2,000
Q4 2020 Feb 11, 2021	SELL	$0.79 - $3.17 $7,426 - $29,801	-9,401 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$0.83 - $1.56 $7,802 - $14,665	9,401 New	9,401 $9,000
Q1 2020 May 01, 2020	SELL	$0.49 - $1.69 $4,784 - $16,501	-9,764 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.05 - $1.66 $7,341 - $11,606	6,992 Added 252.24%	9,764 $14,000
Q3 2019 Nov 14, 2019	BUY	$1.2 - $12.7 $1,112 - $11,772	927 Added 50.24%	2,772 $3,000
Q2 2019 Aug 14, 2019	BUY	$6.37 - $22.56 $11,752 - $41,623	1,845 New	1,845 $21,000

Ticker XBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,166,600
Market Cap $59.6M
Description
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-base...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.